Department of Endoscopy, Hiroshima University Hospital, Hiroshima, 734-0037, Japan.
Department of Health and Science, Prefectural University of Hiroshima, 1-1-71, Ujinahigashi, Minami-ku, Hiroshima, 734-8558, Japan.
Gastric Cancer. 2021 Jul;24(4):937-945. doi: 10.1007/s10120-021-01172-x. Epub 2021 Feb 27.
Eradication therapy is known to be effective against Helicobacter pylori-positive gastric MALT lymphoma but predicting the efficacy of eradication therapy against Helicobacter pylori-negative gastric MALT lymphoma is difficult. Recent reports have shown that non-Helicobacter pylori helicobacter infections induce gastric MALT lymphoma, and we aimed to clarify whether non-Helicobacter pylori helicobacter infections are associated with the efficacy of eradication therapy.
We analyzed eradication therapy as a first-line treatment for 182 cases of gastric MALT lymphoma, classified according to Helicobacter pylori infection and API2-MALT1 mutation status. We also evaluated the non-Helicobacter pylori helicobacter infection status in 29 Helicobacter pylori-negative cases via PCR with DNA extracted from paraffin-embedded biopsy tissues. Finally, we analyzed the relationship between non-Helicobacter pylori helicobacter infection status and eradication therapy outcome.
The API2-MALT1 mutation was observed in 13/182 patients (7.1%), none of whom were cured by eradication therapy. Helicobacter pylori-negative cases had a significantly higher non-Helicobacter pylori helicobacter infection rate than Helicobacter pylori-positive cases (16/29, 55% vs. 3/29, 10%; P < 0.05). Among the Helicobacter pylori-negative cases, non-Helicobacter pylori helicobacter-positive cases had a significantly higher complete response rate than non-Helicobacter pylori helicobacter-negative cases (12/16, 75% vs. 3/13, 23%; P < 0.05).
Helicobacter pylori-negative and API2-MALT1-negative gastric MALT lymphoma cases exhibited a high rate of non-Helicobacter pylori helicobacter infections, which may have contributed to the success of eradication therapy. Therefore, we recommend eradication therapy as a first-line treatment for non-Helicobacter pylori helicobacter-positive gastric MALT lymphoma.
根除疗法已被证实对幽门螺杆菌阳性胃 MALT 淋巴瘤有效,但预测幽门螺杆菌阴性胃 MALT 淋巴瘤的根除疗效较为困难。最近的报告显示,非幽门螺杆菌螺旋菌感染可诱导胃 MALT 淋巴瘤,我们旨在阐明非幽门螺杆菌螺旋菌感染是否与根除疗效相关。
我们分析了 182 例胃 MALT 淋巴瘤患者的根除治疗,根据幽门螺杆菌感染和 API2-MALT1 突变状态进行分类。我们还通过聚合酶链反应(PCR)评估了 29 例幽门螺杆菌阴性病例的非幽门螺杆菌螺旋菌感染状态,使用的是从石蜡包埋活检组织中提取的 DNA。最后,我们分析了非幽门螺杆菌螺旋菌感染状态与根除治疗结果之间的关系。
182 例患者中有 13 例(7.1%)存在 API2-MALT1 突变,这些患者均未通过根除治疗治愈。幽门螺杆菌阴性病例的非幽门螺杆菌螺旋菌感染率明显高于幽门螺杆菌阳性病例(16/29,55%比 3/29,10%;P<0.05)。在幽门螺杆菌阴性病例中,非幽门螺杆菌螺旋菌阳性病例的完全缓解率明显高于非幽门螺杆菌螺旋菌阴性病例(12/16,75%比 3/13,23%;P<0.05)。
幽门螺杆菌阴性和 API2-MALT1 阴性胃 MALT 淋巴瘤病例存在较高的非幽门螺杆菌螺旋菌感染率,这可能有助于根除治疗的成功。因此,我们建议将根除治疗作为非幽门螺杆菌螺旋菌阳性胃 MALT 淋巴瘤的一线治疗。